Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8445585 | European Journal of Cancer | 2012 | 11 Pages |
Abstract
c-Src mediates the essential role of growth pathways in ER negative breast cancer cells. The ER positive and HER2 over-activation are two important predictive biomarkers for the resistance to a c-Src inhibitor. These data provided an important therapeutic rationale for patient selection in clinical trials with c-Src inhibitors in breast cancer.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Ping Fan, Russell E. McDaniel, Helen R. Kim, Dionyssia Clagett, Bassem Haddad, V. Craig Jordan,